Lenvatinib plus pembro for aRCC - update on the CLEAR study

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement

New era of early cancer detection blood tests on the horizon

Tumour-infiltrating lymphocyte treatment for advanced melanoma

Working to improve global cancer care access in low middle-income countries

Breast cancer and survivorship